Nuvation Bio Inc.

NYSE NUVB

Nuvation Bio Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.16

Nuvation Bio Inc. Debt to Equity Ratio is 0.16 for the Trailing 12 Months (TTM) ending September 30, 2024, a 2,334.71% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.
  • Nuvation Bio Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.01, a 21.95% change year over year.
  • Nuvation Bio Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.01.
Key data
Date Debt to Equity Ratio Debt to Income Ratio Debt to Tangible Net Worth Ratio Dividend Coverage Ratio
Market news
Loading...
NYSE: NUVB

Nuvation Bio Inc.

CEO Dr. David T. Hung M.D.
IPO Date Aug. 26, 2020
Location United States
Headquarters 1500 Broadway
Employees 203
Sector Health Care
Industries
Description

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Similar companies

TIL

Instil Bio, Inc.

USD 20.03

5.31%

CTMX

CytomX Therapeutics, Inc.

USD 0.84

-5.23%

ASMB

Assembly Biosciences, Inc.

USD 14.74

-1.01%

StockViz Staff

January 16, 2025

Any question? Send us an email